Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07090499 · ClinicalTrials.gov registry record · Phase 1
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
A Phase 1 study of Head and Neck Cancer and Bladder Cancer, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 310
- Enrollment target
- 20
- Study locations
NCT07090499: Recruiting Phase 1 study of Head and Neck Cancer and Bladder Cancer, sponsored by Pfizer.
NCT07090499 is a Phase 1 study of Head and Neck Cancer and Bladder Cancer that is actively recruiting participants, run by Pfizer. The registered enrollment target is 310 participants, above the 260-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (19% higher). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07090499, a Phase 1 study of Head and Neck Cancer and Bladder Cancer, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 310 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to explore the safety and effects of the study drug (PF-08046876) in people diagnosed with advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas. PF-08046876 is an investigational anticancer therapy called an 'antibody drug conjugate' or 'ADC'. ADCs are anticancer drugs designed to stick to cancer cells and kill them. The study drug will be given to participants through a needle in a vein (intravenous infusion). This study includes multiple parts. In the first part of the study, there will be different groups of people receiving different doses of the study drug. The study may also test different schedules.
Primary Outcome
AEs as characterized by type, frequency, severity, timing, seriousness, and relationship to study therapy dose modifications.
Conditions Studied
Interventions
- DRUG PF-08046876
Study Locations (20)
California
- City of Hope National Medical Center - Duarte
- City of Hope at Irvine Lennar - Irvine
- Ronald Reagan UCLA Medical Center - Los Angeles
- UCLA Department of Medicine-Hematology/Oncology - Los Angeles
- Santa Monica UCLA Medical Center & Orthopaedic Hospital - Santa Monica
- UCLA Hematology/Oncology - Santa Monica - Santa Monica
Texas
- The University of Texas MD Anderson Cancer Center - Conroe - Conroe
- University of Texas MD Anderson Cancer Center - Houston
- The University of Texas, MD Anderson Cancer Center - West Houston - Houston
- The University of Texas, MD Anderson Cancer Center - League City - League City
- NEXT Oncology - San Antonio
Connecticut
- Smilow Cancer Hospital - Yale New Haven Health - New Haven
- Yale - New Haven Hospital - Yale Cancer Center - New Haven
- Smilow Cancer Hospital Phase 1 Unit - New Haven
- Smilow Cancer Hospital - Trumbull - Trumbull
Massachusetts
- Brigham and Women's Hospital - Boston
- Dana-Farber Cancer Institute - Boston
- Dana-Farber Cancer Institute - Chestnut Hill - Newton
Tennessee
- Sarah Cannon Research Institute - Pharmacy - Nashville
- SCRI Oncology Partners - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 310 participants |
| Start Date | 2025-08-20 |
| Est. Completion | 2029-07-08 |
| Phase | Phase 1 |
What NCT07090499 shows while recruiting
NCT07090499 is an interventional study that assigns participants to a tested intervention. The registered 310 participants enrollment target is mid-sized for trials with a published cap, above the 260-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (19% higher).
The record links to 10 conditions, with Head and Neck Cancer appearing as the primary indexed condition, and to 1 intervention - of which PF-08046876 is the first listed.
NCT07090499 names 20 study sites across 5 states, led by California, Texas, Connecticut.
Frequently Asked Questions
What is clinical trial NCT07090499 about?
NCT07090499 is a clinical study titled "A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors". The purpose of the study is to explore the safety and effects of the study drug (PF-08046876) in people diagnosed with advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas. PF-08046876 is an investigational anticancer therapy called an 'antibody drug conjugate' or 'ADC'. ADCs ...
What is the current status of trial NCT07090499?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 310 participants. The study started on 2025-08-20. Estimated completion is 2029-07-08.
What conditions does trial NCT07090499 study?
This clinical trial studies the following conditions: Head and Neck Cancer, Bladder Cancer, Carcinoma, Non-Small Cell Lung, Esophageal Cancer, Urothelial Carcinoma.
What interventions are being tested in trial NCT07090499?
The interventions under investigation include: PF-08046876 (DRUG).
Who is sponsoring clinical trial NCT07090499?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07090499 being conducted?
This trial has 20 study locations across California, Connecticut, Massachusetts, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Head and Neck Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07090499's enrollment target sits among peer trials
310 34th of 250 higher than 217 of 250 other Head and Neck Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Head and Neck Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer
RECRUITING · Phase 1
-
RAPA-201 Therapy of Solid Tumors
RECRUITING · Phase 1
-
Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC
RECRUITING · Phase 1
-
TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers
RECRUITING · Phase 1
-
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Gabapentin & Ketamine for Prevention/Treatment of Acute/Chronic Pain in Locally Advanced Head and Neck Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03039439 · 310 participants
Molecular and Immunohistochemical Profiling of Tumors in Patients With Parathyroid Tumors
- NCT04178018 · 310 participants · NA
Transvaginal Ultrasound and Photoacoustic Imaging of Ovary
- NCT04878094 · 310 participants · Phase 3
A Study of Intra-operative Imaging in Women With Ovarian Cancer
- NCT05459233 · 310 participants · NA
Valve Hemodynamic Optimization Based on Doppler-Echocardiography vs Catheterization Measurements Following ViV TAVR
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI